Carbapenem resistance profiles of Pathogenic *Escherichia coli* in Uganda

Kenneth Ssekatawa

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Denis K Byarugaba

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Jesca L. Nakavuma

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Charles Drago Kato

Makerere University College of veterinary Medicine Animal Resources and Biosecurity

Francis Ejobi

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Robert Tweyongyere

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Eddie M. Wampande (✉ wamps@covab.mak.ac.ug)

Makerere University College of Veterinary Medicine Animal Resources and Biosecurity

Research

Keywords: Carbapenem resistance, Virulence genes, Pathogenicity islands, Pathogenic *E. coli*, *E. coli* phylogenetic groups

Posted Date: November 11th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-103468/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at European Journal of Biology and Biotechnology on April 7th, 2021. See the published version at <https://doi.org/10.24018/ejbio.2021.2.2.171>.

Abstract

Background: *Escherichia coli* has been implicated as one of the main etiological agents of diarrhea, urinary tract infections, meningitis and septicemia worldwide. The ability to cause diseases is potentiated by presence of virulence factors. The virulence factors influence the capacity of *E. coli* to infect and colonize different body systems. Thus, pathogenic *E. coli* are grouped into DEC strains that are mainly clustered in phylogenetic group B1 and A; ExPEC belonging to A, B2 and D. Coexistence of virulence and beta-lactamase encoding genes complicates treatment outcomes. Therefore, this study aimed at presenting the CR profiles among pathogenic *E. coli*.

Methods: This was a retrospective cross-sectional study involving use of archived *E. coli* clinical isolates collected in 2019 from four Ugandan tertiary hospitals. The isolates were subjected to antibiotics sensitivity assays to determine phenotypic resistance. Four sets of multiplex PCR were performed to detect CR genes, DEC pathotypes virulent genes, ExPEC PAI and the *E. coli* phylogenetic groups.

Results:

Antibiotic susceptibility revealed that all the 421 *E. coli* isolates used were MDR as they exhibited 100% resistance to more than one of the first-line antibiotics. The study registered phenotypic and genotypic CR prevalence of 22.8% and 33.0% respectively. The most predominant gene was *bla*OXA-48 with genotypic frequency of 33.0%, then *bla*VIM(21.0%), *bla*IMP(16.5%), *bla*KPC(14.8%) and *bla*NDM(14.8%). Spearman's correlation revealed that presence of CR genes was highly associated with phenotypic resistance. Furthermore, of 421 MDR *E. coli* isolates, 19.7% harboured DEC virulent genes, where EPEC recorded significantly higher prevalence (10.8%) followed by S-ETEC(3.1%), STEC(2.9%), EIEC (2.0%) and L-ETEC(2.0%). Genetic analysis characterized 46.1% of the isolates as ExPEC and only PAI IV536(33.0%) and PAI IICFT073(13.1%) were detected. Phylogenetic group B2 was predominantly detected (41.1%), followed by A(30.2%), B1(21.6%), and D(7.1%). Furthermore, 38.6% and 23.1% of the DEC and ExPEC respectively expressed phenotypic resistance.

Conclusion: Our results exhibited significant level of CR carriage among the MDR DEC and ExPEC clinical isolates belonging to phylogenetic groups B1 and B2 respectively. Virulence and CR genetic factors are mainly located on mobile elements. Thus, constitutes a great threat to the healthcare system as it promotes horizontal gene transfer.

Introduction

Escherichia coli is one of the most prevalent commensals of the human gastro-intestinal tract (GIT) microbiota. However, some *E. coli* are pathogenic. Pathogenic *E. coli* comprises of diarrheagenic *E. coli* (DEC) [1] and Extra-intestinal pathogenic *E. coli* (ExPEC) pathotypes [2]. Diarrheagenic pathotypes are responsible for all gastrointestinal tract *E. coli* infections most importantly diarrhea. Diarrhea is one of the principal causes of illness and death among children under 5 years in developing countries and DEC pathotypes account for the biggest percentage. Reaching protective immunity against DEC in children is hard as DEC is composed of a wide range of pathotypes, hence variant antigens. Extra-intestinal pathogenic *E. coli* is accountable for all *E. coli* associated infections outside the gastrointestinal tract, such as meningitis, urinary tract infections (UTI), pneumonia, septicemia, among others [3-5]. An alarming prevalence of bacterial UTI has been registered in primary healthcare. *Escherichia coli* has been implicated to be the chief etiology of both community and nosocomial acquired UTI worldwide.

Diarrheagenic *E. coli* are grouped into eight pathotypes basing on virulent factors responsible for their pathogenicity. These include Enteropathogenic *E. coli* (EPEC), Enteroinvasive *E. coli* (EIEC), Enteroaggregative *E. coli* (EAEC), Enterotoxigenic *E. coli* (ETEC) and Diffusely Adherent *E. coli* (DAEC), Shiga toxin-producing *E. coli* (STEC) also commonly known as enterohemorrhagic *E. coli* (EHEC) or Verotoxigenic *E. coli* (VTEC), the newly identified adherent invasive *E. coli* (AIEC) which is alleged to be associated with Crohn's disease but not with any diarrheagenic infections and a hybrid pathotype, enteroaggregative hemorrhagic *E. coli* (EAHEC) carrying STEC and EAEC virulence genetic determinants [3]. Thus, pathogenic DEC encompasses a genetically heterogeneous family of *E. coli* with a plastic genome. Several research articles suggest that each pathotype possesses and codes for distinctive virulence and colonization determinants harboured in their genomes distinguishing them from other pathotypes and non-virulent strains. These virulence factors for each pathotype are encoded for by conserved genes and are restricted within geographical boundaries [6, 7]. Therefore, molecular typing of *Escherichia coli* to identify the different DEC pathotypes can be achieved by targeting virulent genes. These virulent genes include; *eae* for typing of EPEC; *stx* for STEC/EHEC; *est* for st-ETEC; *elt* for lt-ETEC *aggR* for EAEC; *ipaH* for EIEC. *eae* gene is translated into Intimin polypeptide which is the key factor for attaching and effacing lesions; *stx* gene encodes for the Shiga-like toxin; *elt* and *est* genes are translated into Thermolabile and Thermostable toxins respectively; *ipaH* gene accounts for invasion capacity and *aggR* gene is translated into a transcriptional activator protein of aggregative adherence fimbriae [8].

The most clinically significant pathotypes of ExPEC are uropathogenic *E. coli* (UPEC) responsible for UTIs and neonatal meningitis *E. coli*, (NMEC) causing meningitis and septicemia [9]. ExPEC pathogenicity is accounted for by presence of virulence factors encoding genes located either on plasmids or chromosomes. These virulent genes are characteristically positioned in particular regions known as pathogenicity islands (PAI) if found on the chromosome [10]. Therefore molecular typing of ExPEC pathotypes can be based on Multiplex PCR amplification of PAI markers previously characterized in UPEC chromosomal genes encoding virulent factors such as hemolysins (*hlyA* and *hlyF*), cytotoxic necrotizing factors (*cnf1* and *cnf2*), colicin V (*cvaC*), aerobactin (*iutA*), yersiniabactin (*fyuA*), salmochelin (*iroN*), P-fimbriae (*papC* and *papG*), S-fimbrial adhesin (*sfaA* and *sfaS*), afimbrial adhesin (*afa*), serum resistance (*iss* and *traT*), brain microvascular endothelium invasion (*ibe10*), K1 capsule (*kpsII* and *K1*), and ompT outer membrane protein (*ompT*) [11, 12].

Furthermore, PCR analysis clusters *E. coli* strains into A, B1, B2, and D phylogenetic groups due to the presence of the *chuA* and *yjaA* genes as well as TSPE4.C2 DNA fragment [13]. The intestinal pathogenic *E. coli* strains belong to groups A, B1 and D, extraintestinal pathogenic *E. coli* strains generally follow under groups B2 and D, while commensal *E. coli* strains to groups A and B1 [13, 14]

High levels antibiotic resistance in Enterobacteriaceae is of great concern to the healthcare system [15, 16]. *Escherichia coli* like other Enterobacteriaceae has evolved to acquire different mechanisms of antibiotic resistance which confer protection to lethal doses of different classes of antibiotics. Carbapenems are the most suitable antibiotics used in the treatment of multidrug resistant (MDR) gram-negative bacteria infections. Studies have documented high prevalence of carbapenem resistant Enterobacteriaceae (CRE) in Uganda [17, 18]. However, the carbapenem resistance profiles of DEC and ExPEC human isolates have not been investigated, yet for meaningful treatment outcomes and prescription decisions, knowledge about pathogen susceptibility patterns to antibiotics in question is very important. Thus, this study was aimed at profiling the carbapenem resistance profiles of intestinal and extraintestinal human pathogenic *E. coli* isolates for genetic markers allied with DEC and ExPEC strains. The study relied on the screening for DEC genetic markers, PAI associated sequences for ExPEC and determination of phylogenetic group and genetic determinants of carbapenem resistance (CR).

Materials And Methods

Study design, site and source of bacteria isolates

This was a cross sectional-laboratory-based study conducted at the Microbiology Laboratory and Molecular Biology Laboratory, College of Veterinary Medicine Animal Resources and Biosecurity (CoVAB) Makerere University. The study involved use of archived MDR *Escherichia coli* samples isolated between January and December, 2019 from clinical specimens in the Microbiology Laboratories of Mulago National Referral Hospital (MNRH), Mbale Regional Referral Hospital (MRRH), Mbarara Regional Referral Hospital (MBRRH) and Kampala International University Teaching Hospital (KIU-TH). The samples were transported in peptone water to the Microbiology Laboratory, CoVAB. Overnight cultures of *E. coli* were prepared by pipetting 1ml of peptone water containing each isolate into 49ml of Luria-Bertani (LB) broth. Glycerol stocks of each different isolate were made by adding 500µl of the overnight LB culture to 500µL of 50% glycerol in a 2ml screw top tube and mixed gently mix. The screw tubes were stored at -80°C until further use.

Biochemical assays to confirm the identity of *E. coli*

To confirm the identity of each isolate, Microgen (Micro-biology International) kits for biochemical assays were employed using procedures described by the manufacturer (www.microgenbioproducts.com).

Screening for carbapenem susceptibility

This was achieved using the Kirby Bauer Disk Diffusion method and the results obtained were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines [19]. Ampicillin (AMP) 25 µg, Amoxicillin/clavulanic acid (AMO) 20/10 µg, trimethoprim-sulfamethoxazole (TMP/SMX) 1.25/23.75 µg, Ciprofloxacin (CIP) 5 µg, Cefuroxime (CXM) 30 µg, Temocillin (TEM) 30 µg, Piperacillin-tazobactam (TPZ) 110 µg, Cefoxitin (FOX) 30 µg, Cefipime (FEP) 30µg, Ceftriaxone (CRO) 30 µg, Ceftazidime (CAZ) 30 µg, Cefotaxime (CTX) 30 µg, Ertapenem (ERT) 10 µg, Meropenem (MEM) 10 µg and Imipenem (IMI) 10 µg (Oxoid United Kingdom) carbapenem antibiotics disks were used. The turbidity of overnight *Escherichia coli* broth was adjusted using peptone water to a standard uniform concentration of 0.5 McFarland. Each *E. coli* isolate was inoculated on Mueller Hinton agar (Oxoid, United Kingdom) plates. Three antibiotic discs were placed about 2.0 cm apart and from the edge of plates, then incubated at 37°C for 24 hours. The diameter zones of growth inhibition were scored in millimeters. For quality control, *E. coli* ATCC 25922 was used as a susceptible strain and *Klebsiella pneumoniae* ATCC BAA-1705 as a positive control.

DNA extraction

Pure colonies of *E. coli* from different samples were selected and each sub-cultured in 5 ml of Luria-Bertani broth using sterile inoculating loop. The bacterial suspension was incubated in shaker incubator at 37°C for 24hrs. Then, 1ml of bacterial suspension was transferred into a 1.5 ml eppendorf tube, centrifuged at 10,000 rpm for 10 minutes. The supernatant was discarded and the pellet was re-suspended in 200µl of Gram-negative bacteria lysis buffer provided in the Qiagen DNA extraction. Bacterial total genomic DNA was extracted following the Qiagen DNA extraction protocol and stored at -20°C until further use.

Molecular characterization of virulent genes and carbapenem resistance determinants

Molecular identification of carbapenem resistance determinants and virulent genes in *Escherichia coli* was carried out using multiplex PCR. Primers used for molecular characterization were obtained from Eurofins Genomics AT GmbH and PCR amplification was performed in a Bio-Rad PTC-200 Thermal Cycler (Bio-Rad, Hercules, CA, USA)

Multiplex PCR amplification of carbapenem resistance genes

The existence of carbapenem resistance genetic determinants was determined using primers targeting *bla*VIM, *bla*IMP, *bla*KPC, *bla*OXA-48, and *bla*NDM that carbapenemase encoding genes, Table 1. For co-amplification of target genes, multiplex PCR was conducted by adapting methods used by Dallenne et al., [20]. Briefly, 2.5 µl of template DNA (100 ng/ µl) was added to 47.5 µl PCR mix containing 200 µM dNTPs (Biomatik, USA), 0.5 µM of each primer pair and 1X PCR Buffer (1.5 mM MgCl₂, 10 mM Tris–HCl, pH 8.3/50 mM KCl) (Biomatik USA) and 1.2 µl of 1U *Taq* DNA Polymerase. Amplification was performed as follows; preliminary denaturation at 95°C for 5 minutes; then denaturation at 95°C for 30 seconds; annealing at 56°C for 30 seconds and elongation at 72°C for 1 minute; and a final elongation at 72°C for 10 minutes. For quality assurance positive and negative control isolates were obtained as a kind donation from the Microbiology Laboratory, College of Health Science, Makerere University. Antibiotics susceptible DSMZ 9377 *Klebsiella pneumoniae* was used as a negative control for all genes. *Klebsiella pneumonia* Nr.8 for NDM-1, *Klebsiella pneumoniae* 714 for OXA-48, *Klebsiella pneumoniae* 211 (T) for KPC, *P. aeruginosa* for IMP (Positive control strains from the Institute of Microbiology, Giessen, Germany) and *E. coli* for the VIM gene, obtained from RESET research collaboration [21] were used as positive controls.

Multiplex PCR components and conditions for *E. coli* pathotyping

Virulent genes *eae* for EPEC; *stx* for STEC/EHEC; *est* for TS-ETEC; *elt* for TL-ETEC; *aggR* for EAEC; *ipaH* for EIEC were amplified by multiplex PCR to characterize the different pathogenic bacteria using primers outlined in Table 2 [8]. Five *E. coli* strains INCQS 00181 (CDC 055 – EPEC), INCQS 00171 (CDC EDL – 933 – EHEC) and INCQS 00170 (CDC EDL – 1284 – EIEC) from Centre for disease control and prevention belonging to the five categories of pathogenic *E. coli* were used as control [22]. Multiplex PCR reaction was performed using [23] modified method to enable the concurrent amplification of all target genes. A final PCR volume of 50µl containing 5µl of 100ng DNA sample, 25µl of 1X PCR Buffer mixed with MgCl₂ (1.5 mM), 1.2 µl of 1U *Taq* DNA Polymerase and dNTPs (200 µM) plus 0.5 µM each primer pair for DEC pathotypes. Sterile distilled deionized water was used to top up to 50µl. The PCR was performed under the following condition; An initial denaturation at 95°C for 5 minutes then 30 amplification cycles at 95°C for 30 second, 50 °C for 30 second, 72 °C for 1 minute, and a final extension at 72 °C for 30 minute

PCR amplification of PAI Markers

Seven different PAI markers designated as PAI I536, II536, IV536, ICFT073, IICFT073, IJ96 and IIJ96 have been previously characterized in UPEC [24], Table 3. Thus, the multiplex PCR used in the detection of PAI Markers, contained 2.5 µl of template DNA (100 ng/µl), 1U *Taq* DNA polymerase (Biomatitk) in 1X PCR buffer (Biomatitk), 200 µM of each dNTP, 2.5mM MgCl₂, and 0.5µM of each primer, Table 3. The program consisted of initial denaturation at 94°C for 5min, followed by 30 cycles of 94°C for 1 minute, 55°C for 1 minute and 72°C for 1minute, with a final extension step at 72°C for 10 minutes [24]. The positive control used in the PCR was J96 O4:K6.

Phylogenetic Classification.

Phylogenetic classification exhibited that the *E. coli* strains belonged to four groups (A, B1, B2, or D) based on the presence of the *chuA* and *yjaA* genes and the DNA fragment (TSPE4.C2). Thus, a multiplex PCR was run to determine the phylogenetic classes of the *E. coli* strains using primers targeting *chuA*, *yjaA* and TSPE4.C2 DNA sequences, Table 4. The PCR amplification was conducted by adapting [13] methods. Briefly, the PCR contained 2.5 µl of template DNA, 1U *Taq* DNA polymerase (Biomatitk, USA) in 1x PCR buffer (Biomatitk), 200 µM dNTP, 2.5mM MgCl₂, and 0.8 µM of each primer, Table 1. Amplification was conducted using the following PCR conditions; initial denaturation at 94°C for 5 minutes, then 30 cycles performed at 94°C for 5 seconds, 54°C for 10 seconds, 72°C for 30 second with a final extension step at 72°C for 5 minutes. Phylogenic groups and subgroups were assigned depending on *chuA*, *yjaA*, and TspE4.C2 gene combinations [13, 14], Table 5.

Data analysis

Data analysis was done using the SPSS version 25 (SPSS Inc., Chicago, IL). Statistical differences were computed by chi-square and Spearman's correlation. A p value ≤ 0.05 indicated substantial statistical difference.

Results

Distribution of *Escherichia coli* isolates in clinical specimen

We obtained a total of 618 MDR *E. coli* isolates whereby 300, 67, 142 and 109 isolates were from MNRH, MRRH, MBRRH and KIU-TH respectively. However, 206 isolates were neither viable (177) nor *E. coli* (29). Thus, this study used a total of 421 isolates, 205 were obtained from MNRH, 52 from MRRH, 62 from MBRRH and 102 from KIU-TH. The isolates were predominantly isolated from urine (170/40.4%), then anal swabs (103/24.5%), wound/pus swabs (62/14.7%), blood (28/6.7%), vaginal swabs, (27/6.4%), sputum (19/4.5%) and tracheal aspirate (12/2.9%), Table 6

Phenotypic carbapenem resistance profiles

The Kirby Bauer disk diffusion method was used to determine the susceptibility patterns of the *E. coli* clinical isolates according to CLSI interpretation. All the isolates demonstrated 100% resistance to Ampicillin and Amoxicillin/clavulanic acid hence were MDR, Table S1. Out of the 421 *E. coli* clinical isolates obtained from the different tertiary hospitals, 96 were resistant to Ertapenem and out of the 96 Ertapenem resistant isolates, 43 (10.2%) were resistant to both Imipenem and Meropenem. Thus, this study registered an overall phenotypic carbapenem resistance prevalence of 22.8%. Furthermore, MRRH recorded the highest phenotypic carbapenem resistance prevalence of 34.6% followed by MBRRH (33.9%), MNRH (22.0%) and KIU-TH (11.8%). Carbapenem resistant *E. coli* were largely isolated from anal swabs (31.1%), followed by urine (24.1%), then wound/pus swabs (17.7%), tracheal aspirate (16.7%), Sputum (15.8%), blood (14.3%) and vaginal swabs (11%), Table 6.

Distribution of carbapenemase encoding genes

Pentaplex PCR amplification revealed that 33.0% (139/421) of the *E. coli* isolates obtained from different tertiary hospitals harbored one or more carbapenemases encoding genes. *E. coli* obtained from MRRH scored the highest genotypic prevalence of carbapenem resistance (28/52=53.9%) followed by MBRRH (28/62=45.2%), MNRH (62/205=30.3%) and KIU-TH (21/102=20.6%). Out of the 139 *E. coli* isolates that possessed carbapenem resistant genes, 18.7% (26/139) contained multiple genes. A total of 176 carbapenemases encoding genes was scored and the most predominant gene recorded was *blaOXA-48* at a prevalence/genotypic frequency of 13.8%/33.0%, trailed by *blaVIM* (8.8%/21.0%), then *blaIMP* (6.9%/16.5%), *blaKPC* (6.2%/14.8%) and *blaNDM* (6.2/14.8%), Tables 7 and 8.

Relationship between carbapenemase encoding genes and phenotypic resistance

This study registered substantial variability between genotypic and phenotypic resistance. Among the carbapenemases genes encountered, *blaVIM* provided phenotypic CR to 97.3% (36/37) *E. coli* isolates that harbored it. This was trailed by *blaIMP* (96.6%), *blaKPC* (80.8%), *blaNDM* (65.4%) and *blaOXA-48* (37.9%),

Table 8. Four isolates were found to co-harbour more than one carbapenemase encoding genes, with *bla*OXA and *bla*NDM co-existing in two isolates, *bla*OXA-48 and *bla*KPC in one isolate and *bla*OXA-48, *bla*KPC and *bla*NDM in one isolate but exhibited no phenotypic resistance, Table S2. Despite of no carbapenemase encoding genes detected, a total of eight (8) isolates (MNRH=3, MBRRH=3 and KIU-TH=2) exhibited phenotypic carbapenem resistance.

Dispersion of in tertiary hospitals and clinical specimens

Diarrheagenic *Escherichia coli* (DEC)

Out of 421 MDR *E. coli* isolates, 19.7% (83/421) harboured virulent genetic determinants. MBRRH had the highest prevalence of DEC (17/62=27.4%) followed by MBRH (12/52=23.1%), KIU-TH (21/102=20.6%) and MNRH (35/205=17.1%). However, the DEC prevalence was not statistically different among hospitals. Among the DEC detected, EPEC pathotype recorded significantly higher prevalence of 10.8% followed by S-ETEC (3.1%), STEC (2.9%), EIEC (2.0%) and L-ETEC (2.0%). Pathotypes EAEC and EHEC were not detected in this study, thus scored a prevalence of 0%. Among clinical specimens, DEC were predominantly isolated from anal swabs (75/83=90.4%) followed by urine (4/83=4.8%), sputum (2/83) blood (1/83) and wound/pus swabs (1/83), Table 9.

Extraintestinal Pathogenic *Escherichia coli* (ExPEC)

Multiplex PCR amplification targeting the pathogenicity islands (PAIs) was used detect ExPEC. The overall prevalence of ExPEC was 46.1% (194/421). *E. coli* isolates possessing PAIs were predominantly obtained from MNRH (105/205=54.2%/105), trailed by MBRRH (31/62=50.0%), MRRH (20/52=38.5%) and then KIU-TH (38/102=37.3%). PAI IV₅₃₆ was the most predominant chromosomal region detected (33.0%) and then PAI II_{CF7073} (13.1%). Furthermore, 20 isolates had both PAI IV₅₃₆ and PAI II_{CF7073}. PAI I₅₃₆, PAI II₅₃₆, PAI I_{CF7073}, PAI I_{J96} and PAI II_{J96} were not amplified. Urine samples registered the highest prevalence of ExPEC. Of the 170 isolates obtained from urine, 72.5% (123) were ExPEC followed by vaginal swabs (17/27=62.9%), blood (17/28=60.7%), wound/pus swabs (30/62=48.4%), Tracheal aspirate (4/12=33.3%), sputum (2/19=10.5%) and anal swabs (2/103=1.9%). The prevalence of ExPEC in urine, vaginal swabs, blood, wound/pus swabs was substantially higher than ExPEC prevalence obtained from tracheal aspirate, sputum and anal swabs, Table 9.

Distribution of the *Escherichia coli* Phylogenetic groups

E. coli (421) isolated from several clinical specimens were characterized into four phylogenetic groups (PG) and six phylogenetic subgroups based on the triplex PCR. *E. coli* belonging to phylogenetic group B2 was predominantly detected and scored a prevalence of 41.1%. This was trailed by phylogenetic group A (30.2%), phylogenetic group B1 (21.6%) and phylogenetic group D (7.1%). *E. coli* belonging to Phylogenetic group A, B2 and D were majorly isolated from urine samples whereas phylogenetic group B1 isolates were mainly obtained from anal swabs, Table 10.

Virulent genes and carbapenem resistance profiles among the phylogenetic groups.

EIEC (*ipaH* gene) was detected in one carbapenem susceptible *E. coli* isolate belonging to phylogenetic group A. PAI II_{CF7073} and PAI IV₅₃₆ were also detected in one carbapenem susceptible and two carbapenem resistant phylogenetic group A isolates respectively. Out of the 83 DEC, 98.8% (82) resided within phylogenetic group B1 and 38.6% (32) expressed phenotypic carbapenem resistance. Furthermore, 86.1% (120 PAI IV₅₃₆ and 47 PAI II_{CF7073}) of the ExPEC were characterized as phylogenetic group B2 of which 21% (41) were resistant to carbapenems. Phylogenetic group D contained 12.4% ExPEC (17 PAI IV₅₃₆ and 07 PAI II_{CF7073}) and 2.1% (4) of the phylogenetic group D ExPEC were resistant. Table 11.

Discussion

Despite the fact that *E. coli* is the leading cause of urinary tract infections and diarrheal infection worldwide, to the best of our knowledge, this is the first study from the East African region to investigate the carbapenem resistance profile, virulence pattern and phylogenetic groups among MDR *E. coli* clinical isolates. Knowledge of the prevalence of pathogenic *E. coli* and their antimicrobial resistance pattern is vital in the designing of strategies to control the spread of such superbugs.

Findings of this study revealed that the overall phenotypic carbapenem resistance prevalence stood at 22.8%. Comparable results were achieved by previous studies in Low Middle Income countries (LMIC) with similar healthcare systems. For example, prevalence of carbapenem resistance in Tanzania was 24% [25], Nigeria 15.2%, 27.4% and 36.8% [26-28], India 31.77% [29]. Contrary, this frequency is higher than carbapenem resistance levels reported in countries like Ghana (7.2%) [30], Morocco 5.99% [31], and Ethiopia 2.73%, [32] with similar healthcare settings but lower than the incidences above 50% reported in South Africa, Egypt and Tunisia [33-37].

Multiplex PCR screening identified carbapenemase encoding genes in 33.0% of the isolates. This genotypic carbapenem resistance prevalence corroborates with earlier studies conducted in the East African region [18, 25, 38] and elsewhere [27, 39] that reported levels ranging from 25% to 40%. Contrary, this frequency is significantly lower than carbapenem genotypic levels reported by studies in Tunisia (76.7%) [40], South Africa (68% and 86%) [33, 34], Egypt (89.6%) [37], Turkey (49.5%) [41]. KPC, VIM, NDM, OXA-48 and IMP are the commonest carbapenemases worldwide [42]. Findings of this study revealed the existence of all those carbapenemases encoding genes in Uganda and OXA-48 was the most predominant gene in contrast with previous studies in the region [18, 25] but in agreement with recent studies in carried out in Africa [31, 33, 36, 40]. OXA-48 carbapenemase was first detected in Turkey and it became epidemic in the Middle East and Mediterranean countries [41]. This indicates that OXA-48 harbouring Enterobacteriaceae have spread widely in sub-Saharan Africa to become to most prevalent.

This study found considerable variation between phenotypic and genotypic resistance. Among the *E. coli* isolates that harboured *bla*VIM gene, 97.3% exhibited phenotypic resistance while for *bla*OXA-48, only 37.9% expressed phenotypic resistance. It is important noting that four isolates coharboured more than one gene each but susceptible to carbapenems. Carbapenemases expressed by OXA-48 and its variant genes possess low carbapenems hydrolyzing activity [43-

45]. This provided an insight into why 62.1% of the isolates which possessed OXA-48-like genes did not exhibit phenotypic resistance. Alteration and reduced expression of the outer membrane proteins that act as drug channels complement enzymes expressed by the resistant genes and this mechanism is highly effective against Ertapenem [45, 46]. Thus, carbapenem resistance is not exclusively due to expression carbapenemases. This explains why not all the isolates that harbored carbapenemase genes were carbapenem insusceptible and why resistance to ertapenem was significantly higher. Despite of absence of carbapenem resistance genes, a total of eight sample displayed phenotypic resistance. Thus, resistance in these isolates may be attributed to (a) a combination of loss of outer membrane proteins (OMPs), (OmpK35 and OmpK36) and overexpression of Extended Spectrum Beta-Lactamases-ESBLs (CTX-Ms or SHV-2) or plasmid-borne AmpC enzymes (ACT-1, CMY-2, CMY-4 or DHA-1) [47, 48] and (b) presence of other carbapenemase such as Guiana extended Spectrum enzyme / integron-borne cephalosporinase (GES/IBC), *Serratia marcescens* enzyme (SME₁₋₃), Not Metalloenzyme carbapenemase (NMC-A), Imipenem-hydrolyzing beta lactamase (IMI), Sao Paulo metallo-lactamase (SPM), German imipenemase (GIM), Seoul imipenemase (SIM) and Kyorin University Hospital metallo-lactamase (KHM) [49].

Enterohemorrhagic *E. coli* (EHEC), enteropathogenic *Escherichia coli* (EPEC), enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteroaggregative *E. coli* (EAEC) and diffusely adherent *E. coli* (DAEC) have been reported as the main causes of diarrheal disease in several parts of Africa, predominantly among young children [50]. This study revealed high prevalence of diarrheagenic MDR *E. coli* clinical isolates obtained from different tertiary hospitals as 19.7% (83/421) of the isolates harboured genetic virulence genetic determinant. Of the 83 DEC pathotypes, EPEC was the most encountered diarrheagenic pathotype (51.0%) followed by S-ETEC, STEC and EIEC and L-ETEC. This correlates well with studies conducted outside the African continent [51, 52]. In contrast, similar studies carried out in sub-Saharan Africa (Tanzania, South Africa and Mozambique) reported EAEC as the most prevalent DEC pathotype [53-57] yet it was not detected in this study. As expected, DEC were predominantly isolated from Anal/fecal swabs. However, 9.6% (8/83) were obtained from other clinical specimens. Indeed, several have isolated DEC pathotypes from other clinical specimens other than stool and have been implicated as some of the causes of hemolytic uremic syndrome [58, 59].

In this study, multiplex PCR was used to target Pathogenicity Islands (PAI). PAIs harbour virulent genes in ExPEC that are responsible for pathogenicity [60-62]. The overall prevalence of ExPEC as revealed by molecular typing of PAI in our study was 46.1% (194/421). Of the two PAIs detected, PAI IV536 also known as high pathogenicity Island (HPI) was substantially dominant with a genotypic frequency of 71.7% and PAI IICFT073 had a frequency of 28.3%. This is in agreement with previous studies [24, 60] which reported PAI IV536 as the most prevalent PAI. The main virulence genes residing in the PAI IV536 and PAI IICFT073 are yersiniabactin siderophore iron-uptake system and *P. fimbriae* as well as iron regulated proteins respectively [61, 63, 64]. A previous study in Uganda reported high prevalence of *E. coli* with *P. fimbriae* virulent factor encoded for by the *pap* gene in UPEC [65] indicating high prevalence of PAI IICFT073 pathotypes. However, this study never attempted to detect genes encoding the yersiniabactin siderophore iron-uptake system in PAI IV536 UPEC; thus, there is no available data about the prevalence of PAI IV536 for comparison purposes. As anticipated, ExPEC that harboured PAIs were majorly isolated from urine and vaginal swabs. However, a total of 55 isolates obtained from blood (17) wound/pus swabs (30), tracheal aspirate (4) anal swabs (2) and sputum (2) harboured PAIs. PAI IJ96 *E. coli* have been reported to be both UPEC and NMNEC [66] but this study did not detect any PAI IJ96. Thus, all the *E. coli* isolates that possessed PAI IV₅₃₆ and PAI IICFT₀₇₃ were deemed to be UPEC.

Phylogenetic analysis revealed that *E. coli* isolates obtained from the four tertiary hospitals located in the Central region (MNRH), Western region (MBRRH), South Western Region (KIU-TH) and Eastern Region (MRRH) belonged to the phylogroups A B1, B2 and D and phylogenetic sub groups A0, A1, B22, B23, D1 and D2. Pathogenic intestinal *E. coli* (DEC) mainly belong to Phylogenetic groups A, B1, and D, commensals to the groups A and B1, and strains usually belong to the groups B2 and D [13, 14]. In our study, phylogenetic analysis predominantly clustered *E. coli* clinical isolates into B2 followed by A, B1 and D and this corroborates with findings from previous studies [67-69]. However, contradicting results have been reported worldwide where A is the most abundantly isolated phylogroup [70-73]. Distribution of *E. coli* phylogroups among different ecological zones is influenced by environment factor; thus, this accounts for variability in prevalence of the phylogenetic groups in different countries [74]. In this study, statistically similar (P value 0.9998) distribution of phylogenetic groups A, B1, B2 and D among regions was observed. This pattern of distributes indicates inter-region transmission of UPEC, DEC and commensals. It was observed that phylogenetic group A, B2 and D strains were majorly isolated from urine and this is in affirmative with all studies that conducted phylogenetic analysis of *E. coli* clinical isolates [67, 75-77] whereas B1 strains were predominantly isolated from anal/fecal swabs, this does not corroborate with previous studies which found phylogroup A strains as the most dominant fecal isolates [72, 73, 78].

World over, an increase in pathogenic and commensal *E. coli* strains harbouring antibiotic resistance determinants has been observed. The situation has been complicated by acquisition of antibiotic resistance by other Enterobacteriaceae as several studies have reported that infections caused by resistant bacteria are hard to treat, lead to increase in treatment costs, morbidity and mortality [79]. Antibiotic resistance in Enterobacteriaceae is mainly mediated by beta-lactamase enzymes that inactivate beta-lactam antibiotics by hydrolyzing the peptide bond of the beta-lactam ring. Among the beta-lactamases, carbapenemases are the most important because acquisition of carbapenem resistance genes confer resistance to all beta lactam antibiotics. Furthermore, carbapenem are the most suitable choice antibiotics for treatment of MDR Gram-Negative bacterial infections; [43] thus, infection with carbapenem resistant bacteria significantly prolong the period of stay in hospital and responsible for 10% mortality [80]. Thus, in this study we assessed the carriage of carbapenem resistance and virulence genetic factors among *E. coli* phylogroups. We observed that among the 83 isolates that harboured virulence genetic determinants for DEC, 98.8% (82) and 1.2% (1) belonged to phylogenetic group B1 and A respectively and 38.6% (32) expressed phenotypic resistance. Whereas 86.1% (167), 12.4% (24) and 1.6% (3) of the isolates that had PAIs were characterized as phylogroups B2, D and A respectively and 24.1% (47) were carbapenem resistant. Coexistence of virulence factors and carbapenem resistance was observed in 18.8% (79/421) of the total isolates. Our findings show that carbapenemases production was significantly higher in B1 and B2 (P<0.0001). This is extremely scaring as DEC and ExPEC mainly fall under phylogenetic groups B1 and B2 respectively. Furthermore, existence of virulence genes and genetic determinants of resistance in phylogenetic groups A and D where commensal mainly fall should be treated as a major threat as they are considered to reservoirs of genetic determinants of virulence and antibiotic resistance and they donate these traits to the pathogenic strains of phylogroups B1 and B2 through horizontal gene transfer, arbitrated regularly by plasmids and transposons [44]. Indeed,

previous studies observed that PAIs are mobile genetic elements (transposons) that are transferred from one *E. coli* strain to another through horizontal gene transfer mediated by bacteriophages, conjugative plasmids, conjugation and homologous DNA recombination [64, 81, 82]

Conclusion

Our data indicate high level of carriage of carbapenem resistance among the DEC and ExPEC clinical isolates belonging to phylogenetic group B1 and B2 respectively. DEC and ExPEC pathogenicity and antimicrobial resistance are mediated by genetic factors such as chromosomal/plasmid borne virulence and antibiotic resistance genes as well as chromosomal PAIs virulent genes. Plasmid and PAIs are mobile genetic elements that facilitate horizontal gene transfer contributing to plasticity of the genome. In light of this, routine genetic analysis of *E. coli* clinical and environment isolates is important to better understand the level of pathogenicity and antimicrobial as this will inform the possible burden such isolates are likely to pose to the healthcare system.

List Of Abbreviations

MDR: Multidrug-resistant

PAI: Pathogenicity Island

UTI: Urinary tract infection

UPEC: Uropathogenic *coli*

MNRH: Mulago National Referral Hospital

MRRH: Mbale Regional Referral Hospital

MBRRH: Mbarara Regional Referral Hospital

KIU-TH: Kampala International University-Teaching Hospital

COVAB: College of Veterinary Medicine Animal Resources and Biosecurity

AMP: Ampicillin

AMO: Amoxicillin/clavulanic acid

CIP Ciprofloxacin

CXM: Cefuroxime

TEM: Temocillin

TPZ: Piperacillin-tazobactam

FOX: Cefoxitin

FEP: Cefipime

CRO: Ceftriaxone

CAZ: Ceftazidime

CTX: Cefotaxime

ERT: Ertapenem

IMI: Imipenem

MEM: Meropenem

ATCC: American Type Cell Cultures

bla: beta lactamase

KPC: *Klebsiella pneumoniae* Carbapenemase

NDM: New Delhi Metallo- β -lactamase

VIM: Verona Integron-encoded Metallo- β -lactamase

IMP: Imipenemase Metallo- β -lactamase

OXA: Oxacillinase

DEC: Diarrheagenic *coli*

ExPEC: Extra-intestinal pathogenic *coli*

EPEC: Enteropathogenic *E. coli*

EAEC: Enteroaggregative *E. coli*

EIEC: Enteroinvasive *E. coli*

DAEC: Diffusely adherent *E. coli*

EHEC: Enterohemorrhagic *E. coli*

STEC: Shiga Toxin producing *E. coli*

ETEC: Enterotoxigenic *E. coli*

CRE: Carbapenem resistant Enterobacteriaceae

NMEC: Neonatal meningitis *coli*

OMP: outer membrane protein

EAHEC: enteroaggregative hemorrhagic *coli*

VTEC: Verotoxigenic *coli*

PG: Phylogenetic groups

PSG: Phylogenetic sub groups

GES/IBC: Guiana extended Spectrum enzyme / integron-borne cephalosporinase

SME: *Serratia marcescens* enzyme

NMC: Not Metalloenzyme carbapenemase

IMI: Imipenem-hydrolyzing beta lactamase

SPM: Sao Paulo metallo-lactamase

GIM: German imipenemase (GIM),

SIM: Seoul imipenemase

KHM: Kyorin University Hospital metallo-lactamase

Declarations

Ethics and consent to participate: Ethical Approval No: MHREC1611 was granted by the Research and Ethics Committee for ethical review and approval, Mulago National Referral Hospital. The Research Ethics Committee waived the need for informed consent to use already coded archived samples in this study.

Consent for publication: Not applicable

Funding: The authors declare that this research project was funded by Africa Centre of Excellence in Materials, Product Development & Nanotechnology; MAPRONANO ACE, Grant No. P151847IDA credit 5797-UG, College of Engineering Design Art and Technology, Makerere University.

Availability of Data and Materials: All data generated by this study have been submitted with this manuscript. Raw data and any other forms data generated by this project can be obtained from the authors on request by e-mail.

Competing interests: The authors declare that they have no competing interests

Authors' contributions

This work was carried out in collaboration between all authors. Denis K. Byarugaba (BKB), Eddie Wampande (EW), Francis Ejobi (FE), Jesca L. Nakavuma (JLN), Robert Tweyongere (RT) and Charles Kato Drago (CKD) conceptualized and designed the format for this study. Kenneth Ssekatawa (KS) carried out all

the Laboratory experiments. KS, CKD and EW conducted data analysis. All authors drafted and managed manuscript revisions. All authors read and approved the final manuscript.

Acknowledgements

We are thankful to MAPRONANO ACE funding this work.

References

1. Ali, M.M.M., et al., *Molecular characterization of diarrheagenic Escherichia coli from Libya*. 2012. **86**(5): p. 866-871.
2. Sader, H.S., et al., *Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers*. 2002. **44**(3): p. 273-280.
3. Kaper, J.B., J.P. Nataro, and H.L.J.N.r.m. Mobley, *Pathogenic escherichia coli*. 2004. **2**(2): p. 123-140.
4. Russo, T.A. and J.R.J.T.J.o.i.d. Johnson, *Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC*. 2000. **181**(5): p. 1753-1754.
5. Smith, J.L., et al., *Extraintestinal pathogenic Escherichia coli*. 2007. **4**(2): p. 134-163.
6. Aranda, K.R., et al., *Single multiplex assay to identify simultaneously enteropathogenic, enteroaggregative, enterotoxigenic, enteroinvasive and Shiga toxin-producing Escherichia coli strains in Brazilian children*. 2007. **267**(2): p. 145-150.
7. Brandal, L.T., et al., *Octaplex PCR and fluorescence-based capillary electrophoresis for identification of human diarrheagenic Escherichia coli and Shigella spp.* 2007. **68**(2): p. 331-341.
8. Diamant, E., et al., *Phylogeny and strain typing of Escherichia coli, inferred from variation at mononucleotide repeat loci*. 2004. **70**(4): p. 2464-2473.
9. Clements, A., et al., *Infection strategies of enteric pathogenic Escherichia coli*. 2012. **3**(2): p. 71-87.
10. Johnson, J.R. and A.L.J.T.J.o.i.d. Stell, *Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise*. 2000. **181**(1): p. 261-272.
11. Johnson, T.J., et al., *Identification of minimal predictors of avian pathogenic Escherichia coli virulence for use as a rapid diagnostic tool*. Journal of clinical microbiology, 2008. **46**(12): p. 3987-3996.
12. Le Bouguenec, C., M. Archambaud, and A.J.J.o.c.m. Labigne, *Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction*. 1992. **30**(5): p. 1189-1193.
13. Clermont, O., S. Bonacorsi, and E. Bingen, *Rapid and simple determination of the Escherichia coli phylogenetic group*. Applied environmental microbiology, 2000. **66**(10): p. 4555-4558.
14. Barzan, M., D. Gharibi, and M. Ghorbanpoor, *Phylogenetic grouping and phenotypic detection of extended-spectrum β -lactamases among Escherichia coli from calves and dairy cows in Khuzestan, Iran*. HAJI, HAJIKOLAEI MOHAMMAD RAHIM POURMEHDI, BOROUJENI MEHDI 2017.
15. Johnson, A.P. and N.J.J.o.m.m. Woodford, *Global spread of antibiotic resistance: the example of New Delhi metallo- β -lactamase (NDM)-mediated carbapenem resistance*. 2013. **62**(4): p. 499-513.
16. Partridge, S.R.J.P., *Resistance mechanisms in Enterobacteriaceae*. 2015. **47**(3): p. 276-284.
17. Ssekatawa, K., et al., *A systematic review: the current status of carbapenem resistance in East Africa*. BMC Res Notes, 2018. **11**(1): p. 629.
18. Okoche, D., et al., *Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda*. 2015. **10**(8): p. e0135745.
19. CLSI., *Performance Standards for Antimicrobial Disk Susceptibility Tests for Bacteria Isolated from Animals: CLSI Supplement VET01S; Replaces VET01-S2*. 2015: Clinical and Laboratory Standards Institute.
20. Dallenne, C., et al., *Development of a set of multiplex PCR assays for the detection of genes encoding important β -lactamases in Enterobacteriaceae*. 2010. **65**(3): p. 490-495.
21. Fischer, J., et al., *Escherichia coli producing VIM-1 carbapenemase isolated on a pig farm*. 2012. **67**(7): p. 1793-1795.
22. Ochman, H. and R.K.J.J.o.b. Selander, *Standard reference strains of Escherichia coli from natural populations*. 1984. **157**(2): p. 690-693.
23. Toma, C., et al., *Multiplex PCR assay for identification of human diarrheagenic Escherichia coli*. 2003. **41**(6): p. 2669-2671.
24. Sabaté, M., et al., *Pathogenicity island markers in commensal and uropathogenic Escherichia coli isolates*. 2006. **12**(9): p. 880-886.
25. Mushi, M.F., et al., *Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania*. 2014. **2014**.
26. Ogbolu, D. and M.J.I.j.o.a.a. Webber, *High-level and novel mechanisms of carbapenem resistance in Gram-negative bacteria from tertiary hospitals in Nigeria*. 2014. **43**(5): p. 412-417.
27. Olalekan, A., et al., *High proportion of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae among extended-spectrum β -lactamase-producers in Nigerian hospitals*. J Glob Antimicrob Resist, 2020. **21**: p. 8-12.
28. Oduyebo, O.O., et al., *Phenotypic determination of carbapenemase producing enterobacteriaceae isolates from clinical specimens at a tertiary hospital in Lagos, Nigeria*. Niger Postgrad Med J, 2015. **22**(4): p. 223-7.
29. Pawar, S.K., et al., *Carbapenem-resistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India*. 2018. **5**(3): p. 342-347.

30. Hackman, H.K., et al., *Emergence of Carbapenem-resistant Enterobacteriaceae among Extended-spectrum Beta-lactamase Producers in Accra, Ghana*. 2017. **7**(24).
31. Mahrach, Y., et al., *Phenotypic and molecular study of carbapenemase-producing Enterobacteriaceae in a regional hospital in northern Morocco*. 2019. **3**: p. 113.
32. Eshetie, S., et al., *Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia*. Antimicrobial Resistance and Infection Control, 2015. **4**(1): p. 12.
33. Perovic, O., et al., *Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018*. European Journal of Clinical Microbiology & Infectious Diseases, 2020. **39**(7): p. 1287-1294.
34. Singh-Moodley, A. and O.J.B.i.d. Perovic, *Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa*. 2016. **16**(1): p. 536.
35. Kotb, S., et al., *Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare-associated Infections Surveillance Data, 2011–2017*. 2020. **9**(1): p. 1-9.
36. ElMahallawy, H.A., et al., *Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt*. 2018. **50**(2): p. 560-564.
37. Tawfick, M.M., et al., *The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients*. European Journal of Clinical Microbiology & Infectious Diseases, 2020. **39**(7): p. 1251-1259.
38. Ampaire, L.M., et al., *Epidemiology of carbapenem resistance among multi-drug resistant enterobacteriaceae in Uganda*. 2015. **8**(2): p. 418.
39. Mahmoud, N.E., H.N. Altayb, and R.M. Gurashi, *Detection of Carbapenem-Resistant Genes in <i>Escherichia coli</i> Isolated from Drinking Water in Khartoum, Sudan*. Journal of Environmental and Public Health, 2020. **2020**: p. 2571293.
40. Kollenda, H., et al., *Screening for carbapenemases in ertapenem-resistant Enterobacteriaceae collected at a Tunisian hospital between 2014 and 2018*. 2019. **9**(1): p. 9-13.
41. Baran, I. and N.J.A.o.c.m. Aksu, *Phenotypic and genotypic characteristics of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Turkey*. %J Annals of clinical microbiology antimicrobials, 2016. **15**(1): p. 20.
42. Demir, Y., Y. Zer, and I.J.P.j.o.p.s. Karaoglan, *Investigation of VIM, IMP, NDM-1, KPC AND OXA-48 enzymes in Enterobacteriaceae strains*. 2015. **28**.
43. Nordmann, P., L. Dortet, and L.J.T.i.m.m. Poirel, *Carbapenem resistance in Enterobacteriaceae: here is the storm!* 2012. **18**(5): p. 263-272.
44. Nordmann, P., T. Naas, and L. Poirel, *Global spread of Carbapenemase-producing Enterobacteriaceae*. Emerg Infect Dis, 2011. **17**(10): p. 1791-8.
45. Codjoe, F.S. and E.S. Donkor, *Carbapenem Resistance: A Review*. Med Sci (Basel), 2017. **6**(1).
46. Bou, G., et al., *Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases*. J Clin Microbiol, 2000. **38**(9): p. 3299-305.
47. Crowley, B., V. Benedí, and A. Doménech-Sánchez, *Expression of SHV-2 beta-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems*. Antimicrob Agents Chemother, 2002. **46**(11): p. 3679-82.
48. Yang, D., Y. Guo, and Z.J.C.m. Zhang, *Combined porin loss and extended spectrum β -lactamase production is associated with an increasing imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains*. 2009. **58**(4): p. 366.
49. Queenan, A. and K. Bush, *Carbapenemases: the versatile beta-lactamases*. Clin Microbiol Rev, 2007. **20**(3): p. 440-58, table of contents.
50. Okeke, I.N.J.T.j.o.i.i.d.c., *Diarrheagenic Escherichia coli in sub-Saharan Africa: status, uncertainties and necessities*. 2009. **3**(11): p. 817-842.
51. Keskimäki, M., et al., *Prevalence of diarrheagenic Escherichia coli in finns with or without diarrhea during a round-the-world trip*. J Clin Microbiol, 2000. **38**(12): p. 4425-9.
52. Zhou, Y., et al., *Characteristics of diarrheagenic Escherichia coli among children under 5 years of age with acute diarrhea: a hospital based study*. 2018. **18**(1): p. 63.
53. Mandomando, I.M., et al., *Etiology of diarrhea in children younger than 5 years of age admitted in a rural hospital of southern Mozambique*. Am J Trop Med Hyg, 2007. **76**(3): p. 522-7.
54. Aijuka, M., et al., *Enteroggregative Escherichia coli is the predominant diarrheagenic E. coli pathotype among irrigation water and food sources in South Africa*. Int J Food Microbiol, 2018. **278**: p. 44-51.
55. Tanih, N., et al., *Prevalence of diarrheagenic Escherichia coli in young children from rural South Africa: The Mal-ED cohort*. 2014. **21**: p. 149.
56. Moyo, S.J., et al., *Identification of diarrheagenic Escherichia coli isolated from infants and children in Dar es Salaam, Tanzania*. BMC Infectious Diseases, 2007. **7**(1): p. 92.
57. Bisi-Johnson, M.A., et al., *Molecular basis of virulence in clinical isolates of Escherichia coli and Salmonella species from a tertiary hospital in the Eastern Cape, South Africa*. 2011. **3**(1): p. 9.
58. Nataro, J.P. and J.B. Kaper, *Diarrheagenic Escherichia coli*. Clin Microbiol Rev, 1998. **11**(1): p. 142-201.
59. Herzog, K., et al., *Diarrheagenic enteroaggregative Escherichia coli causing urinary tract infection and bacteremia leading to sepsis*. Infection, 2014. **42**(2): p. 441-444.
60. Tangi, S.C., et al., *Prevalence of pathogenicity island markers genes in uropathogenic Escherichia coli isolated from patients with urinary tract infectious*. Asian Pacific Journal of Tropical Disease, 2015. **5**(8): p. 662-666.
61. Middendorf, B., et al., *The Pathogenicity Islands (PAIs) of the Uropathogenic Escherichia coli Strain 536: Island Probing of PAI II536*. The Journal of Infectious Diseases, 2001. **183**(Supplement_1): p. S17-S20.

62. Parham, N.J., et al., *Prevalence of pathogenicity island IICFT073 genes among extraintestinal clinical isolates of Escherichia coli*. J Clin Microbiol, 2005. **43**(5): p. 2425-34.
63. Sarowska, J., et al., *Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports*. Gut Pathogens, 2019. **11**(1): p. 10.
64. Desvaux, M., et al., *Pathogenicity Factors of Genomic Islands in Intestinal and Extraintestinal Escherichia coli*. 2020. **11**(2065).
65. Katongole, P., et al., *Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic Escherichia coli isolated from clinical isolates in Uganda*. BMC Infectious Diseases, 2020. **20**(1): p. 453.
66. Schmidt, H. and M. Hensel, *Pathogenicity islands in bacterial pathogenesis*. Clin Microbiol Rev, 2004. **17**(1): p. 14-56.
67. Odoki, M., et al., *Phylogenetic analysis of multidrug resistant E. coli isolates from the urinary tract in Bushenyi district, Uganda using the new Clermont phylotyping method*. 2020. **14**(2): p. 51-64.
68. Iranpour, D., et al., *Phylogenetic Groups of <i>Escherichia coli</i> Strains from Patients with Urinary Tract Infection in Iran Based on the New Clermont Phylotyping Method*. BioMed Research International, 2015. **2015**: p. 846219.
69. Ahumada-Santos, Y.P., et al., *Association of phylogenetic distribution and presence of integrons with multidrug resistance in Escherichia coli clinical isolates from children with diarrhoea*. Journal of Infection and Public Health, 2020. **13**(5): p. 767-772.
70. Stoppe, N.C., et al., *Worldwide Phylogenetic Group Patterns of Escherichia coli from Commensal Human and Wastewater Treatment Plant Isolates*. Front Microbiol, 2017. **8**: p. 2512.
71. Duriez, P., et al., *Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations*. Microbiology (Reading), 2001. **147**(Pt 6): p. 1671-1676.
72. Li, B., et al., *Phylogenetic Groups and Pathogenicity Island Markers in Fecal Escherichia coli Isolates from Asymptomatic Humans in China*. 2010. **76**(19): p. 6698-6700.
73. Al-Mayahie, S.M., et al., *Phylogenetic grouping of dominant fecal escherichia coli isolates from healthy males and females in Al-Kut/Wasit Province*. 2015. **6**.
74. Escobar-Pa´ramo, P., et al., *Large-scale population structure of human commensal Escherichia coli isolates*. Appl. Environ. Microbiol. 70:5698–5700., 2004.
75. Lee, J.H., et al., *Phylogenetic group distributions, virulence factors and antimicrobial resistance properties of uropathogenic Escherichia coli strains isolated from patients with urinary tract infections in South Korea*. 2016. **62**(1): p. 84-90.
76. Kazemnia, A., M. Ahmadi, and M. Dilmaghani, *Antibiotic resistance pattern of different Escherichia coli phylogenetic groups isolated from human urinary tract infection and avian colibacillosis*. Iran Biomed J, 2014. **18**(4): p. 219-24.
77. Staji, H., M. Rassouli, and S. Jourablou, *Comparative virulotyping and phylogenomics of Escherichia coli isolates from urine samples of men and women suffering urinary tract infections*. Iran J Basic Med Sci, 2019. **22**(2): p. 211-214.
78. Bailey, J.K., et al., *Distribution of Human Commensal Escherichia coli Phylogenetic Groups*. 2010. **48**(9): p. 3455-3456.
79. Poirel, L., et al., *Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli*. 2016. **16**(3): p. 281.
80. Tischendorf, J., R.A. de Avila, and N. Safdar, *Risk of infection following colonization with carbapenem-resistant Enterobacteriaceae: A systematic review*. Am J Infect Control, 2016. **44**(5): p. 539-43.
81. Middendorf, B., et al., *Instability of pathogenicity islands in uropathogenic Escherichia coli 536*. 2004. **186**(10): p. 3086-3096.
82. Schneider, G., et al., *Mobilisation and remobilisation of a large archetypal pathogenicity island of uropathogenic Escherichia coli in vitrosupport the role of conjugation for horizontal transfer of genomic islands*. 2011. **11**(1): p. 210.

Tables

Table 1: Carbapenem resistance genes and respective primers

Gene	Primer sequence (5 ¹ -3 ¹)	Band size (Bp)	Reference
<i>BlaKPC</i>	F-ATG TCA CTG TAT CGC CGT CT R-TTT TCA GAG CCT TAC TGC CC	538	[20]
<i>BlaIMP</i>	F-TGA GCA AGT TAT CTG TAT TC R-TTA GTT GCT TGG TTT TGA TG	139	[20]
<i>BlaVIM</i>	F-GAT GGT GTT TGG TCG CAT A R-CGA ATG CGC AGC ACC AG	390	[20]
<i>BlaNDM</i>	F-GGT TTG GCG ATC TGG TTT TC R-CGG AAT GGC TCA TCA CGA TC	822	[20]
<i>BlaOXA-48</i>	F-TTG GTG GCA TCG ATT ATC GG R- GAG CAC TTC TTT TGT GAT GGC	281	[20]

Table 2: Genes and their prime sequences for molecular typing of E. coli (adopted from Dias et al., 2012)

Gene	Primer Sequence (5'-3')	Size of amplicon (Bp)	Annealing Temp (°C)	Reference
eae	CCCGAATTCGGCACAAGCATAAGC CCCGGATCCGTCTCGCCAGTATTCG	881	50	[24]
stx	GAGCGAAATAATTTATATGTG TGATGATGGCAATTCAGTAT	518	50	[25]
est	ATTTTMTTCTGTATTRTCTT CACCCGGTACARGCAGGATT	190	50	[26]
elt	GGCGACAGATTATACCGTGC CGGTCTCTATATCCCTGTT	450	50	[26]
paH	GTTCTTGACCGCCTTTCGATACCGTC GCCGGTCAGCCACCCTCTGAGAGTAC	619	50	[27]
aggR	GTATACACAAAAGAAGGAAGC ACAGAATCGTCAGCATCAGC	254	50	[28]

Table 3: Oligonucleotides used to amplify PAI markers harboring virulent genetic determinants

s	Primer sequence (5'-3')	Amplicon size (bp)	Virulent factors expressed by genes harboured by PAI markers	Reference
36	TAA TGC CGG AGA TTC ATT GTC AGG ATT TGT CTC AGG GCT TT	1800	α -Haemolysin, CS12 fimbriae, and F17-like fimbrial adhesin	[24]
36	CAT GTC CAA AGC TCG AGC C CTA CGT CAG GCT GGC TTT G	1000	α -Haemolysin and P-related fimbriae	[24]
536	AAG GAT TCG CTG TTA CCG GAC TCG TCG GGC AGC GTT TCT TCT	300	Yersiniabactin siderophore system	[24]
73	GGA CAT CCT GTT ACA GCG CGC A TCG CCA CCA ATC ACA GC GAA C	930	α -Haemolysin, P-fimbriae, and aerobactin	[24]
73	ATG GAT GTT GTA TCG CG ACG AGC ATG TGG ATC TGC	400	P-fimbriae and iron-regulated genes	[24]
6	TCG TGC TCA GGT CCG GAA TTT TGG CAT CCC ACA TTA TCG	400	α -Haemolysin and P-fimbriae	[24]
96	GGA TCC ATG AAA ACA TGG TTA ATG GG GAT ATT TTT GTT GCC ATT GGT TAC C	2300	α -Haemolysin, Prs-fimbriae, and cytotoxic necrotizing factor 1	[24]

Table 4: Primers used in phylogenetic analysis of *E. coli*

	Primer sequence (5'-3')	Amplicon size (bp)	Protein expressed	Reference
	GAC GAA CCA ACG GTC AGG AT TGC CGC CAG TAC CAA AGA CA	279	Hemetransport in enterohemorrhagic O157:H7 <i>E. coli</i>	[13]
	TGA AGT GTC AGG AGA CGC TG ATG GAG AAT GCG TTC CTC AAC	211	Protein function unknown	[13]
4.C2	GAG TAA TGT CGG GGC ATT CA CGC GCC AAC AAA GTA TTA CG	152	Putative DNA fragment (TSPE4.C2) in <i>E. coli</i>	[13]

Table 5: *chuA*, *yjaA*, and *TspE4.C2* gene combinations for assigning of phylogenetic groups and subgroups of *Escherichia coli*

TSECP4C2	yjaA	ChuA	Phylogenetic group	Phylogenetic subgroup
Negative	Negative	Negative	A	A0
Negative	Positive	Negative	A	A1
Positive	Negative	Negative	B1	B1
Negative	Positive	Positive	B2	B22
Positive	Positive	Positive	B2	B23
Negative	Negative	Positive	D	D1
Positive	Negative	Positive	D	D2

Table 6: Phenotypic carbapenem resistance profiles of *E. coli* samples isolated from several clinical specimens at different tertiary hospitals in Uganda

Clinical Specimen	MNRH		MRRH		MBRRH		KIU-TH		Total		CR Prevalence per clinical specimen (%)
	n	CR	n	CR	n	CR	n	CR	n	CR	
Urine	86	19	16	5	30	12	38	5	170	41	24.1
Blood	19	3	3	1	0	0	6	0	28	4	14.3
Anal swab	41	17	14	6	20	5	28	4	103	32	31.1
Wound/pus swab	38	4	4	2	12	4	8	1	62	11	17.7
Sputum	0	0	14	3	0	0	5	0	19	3	15.8
Tracheal Aspirate	6	0	1	1	0	0	5	1	12	2	16.7
Virginal Swab	15	2	0	0	0	0	12	1	27	3	11.1
Total	205	45	52	18	62	21	102	12	421	96	22.8
CR Prevalence (%)	22.0		34.6		33.9		11.8		22.8		

n= population or number of samples and CR stands for carbapenem resistance

Table 8: Correlation between carbapenem resistance genes and phenotypic resistance

Tertiary Hospital	Carbapenemase encoding genes										Total
	VIM		OXA-48		IMP		KPC		NDM		
	R	S	R	S	R	S	R	S	R	S	
MNRH	21	0	9	14	6	0	12	3	9	6	80
MRRH	4	0	5	7	12	0	4	0	6	2	40
MBRRH	6	0	8	8	7	1	3	0	2	0	35
KIU	5	1	0	7	3	0	2	2	0	1	21
Total	36	1	22	36	28	1	21	5	17	9	176
Prevalence (%)	8.8		13.8		6.9		6.2		6.2		
Phenotypic CR (%)	97.3		37.9		96.6		80.8		65.4		
Genotypic frequency (%)	21.0		33.0		16.5		14.8		14.8		

R: Resistant, S: Sensitive

Table 11: Distribution of pathogenic genes among the *Escherichia coli* *Phylogenetic groups and their carbapenem resistance profiles*

PG	PSG	Virulent genes found in DEC pathotypes										Pathogenicity Islands that harbor virulent genes in ExPEC			
		eae		elt		ipaH		sxt		est		PAI IICFT073		PAI IV536	
		R	S	R	S	R	S	R	S	R	S	R	S	R	S
A	A0	0	0	0	0	0	1	0	0	0	0	0		0	0
	A1	0	0	0	0	0	0	0	0	0	0	0		1	2
B1	B1	19	23	4	4	3	4	3	9	3	10	0		0	0
B2	B22	0	0	0	0	0	0	0	0	0	0	2		1	4
	B23	0	0	0	0	0	0	0	0	0	0	15		29	20
D	D1	0	0	0	0	0	0	0	0	0	0	1		5	0
	D2	0	0	0	0	0	0	0	0	0	0	0		1	3
Total		42		8		8		12		13		55		139	

PG: Phylogenetic group, PSG: Phylogenetic subgroup

Table 7: Distribution of carbapenem resistant genes in *E. coli* isolates obtained from different tertiary hospitals in Uganda

Referral Hospital	n	Carbapenemase encoding genes														Total CR isolates	Prevalence (%)
		NDM	KPC	IMP	OXA-48	VIM	NDM & OXA-48	IMP & NDM	KPC & OXA-48	IMP & OXA-48	VIM & OXA-48	VIM, NDM & OXA-48	NDM, KPC & OXA-48	IMP, NDM & OXA-48	IMP, VIM & OXA-48		
MNRH	205	07	07	06	11	19	02	-	04	-	-	02	04	-	-	62	30.3
MRRH	52	03	04	05	07	02	-	02	-			-	-	03	02	28	53.9
MBRRH	62	02	03	03	09	04	-	-	-	05	02	-	-	-	-	28	45.2
KIU-TH	102	01	04	03	07	06	-	-	-	-	-	-	-	-	-	21	20.6
Total	421															139	33.0

Table 9: Distribution of pathogenic *E. coli* among the tertiary hospitals and clinical samples

Tertiary hospitals						Clinical specimens						
Pathotype	MNRH	MRRH	MBRRH	KIU-TH	Total/ prevalence	Urine	Blood	Anal Swabs	Wound/ pus swabs	Sputum	Tracheal aspirate	Virginal swabs
eae/EPEC	21 (10.2%)	2 (3.9%)	8 (12.9%)	11 (10.8%)	42 (10.0%)	3 (1.8%)	1 (3.6%)	37 (35.9%)	1 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
elt/L- ETEC	3 (1.5%)	2 (3.9%)	1 (1.6%)	2 (2.0%)	8 (2.0%)	1 (0.6%)	0 (0.0%)	6 (5.8%)	0 (0.0%)	1 (5.3%)	0 (0.0%)	0 (0.0%)
est/S- ETEC	3 (1.5%)	3 (5.8%)	4 (6.5%)	3 (2.9%)	13 (3.1%)	0 (0.0%)	0 (0.0%)	13 (12.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
stx/STEC	4 (2.0%)	2 (3.9%)	3 (4.8%)	3 (2.9%)	12 (2.9%)	0 (0.0%)	0 (0.0%)	11 (10.7%)	0 (0.0%)	1 (5.3%)	0 (0.0%)	0 (0.0%)
DEC	2 (1.0%)	3 (5.8%)	1 (1.6%)	2 (2.0%)	8 (2.0%)	0 (0.0%)	0 (0.0%)	8 (7.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
ipaH/EIEC PAI	21 (10.2%)	4 (7.7%)	23 (37.1%)	7 (6.9%)	55/13.1%	34 (20%)	9 (32.1%)	0 (0.0%)	9 (14.5%)	0 (0.0%)	0 (0.0%)	4 (14.8%)
IICFT073	84 (41.0%)	16 (30.8%)	8 (13.0%)	31 (30.4%)	139/33.0%	89 (52.5%)	8 (28.6)	2 (1.9%)	21 (33.9%)	2 (10.5%)	4 (33.3%)	13 (48.1%)
ExPEC	PAI IV536	(41.0%)	(30.8%)	(13.0%)	(30.4%)	(52.5%)	(28.6)	(1.9%)	(33.9%)	(10.5%)	(33.3%)	(48.1%)

Table 10: Distribution of the *Escherichia coli* Phylogenetic groups in the four tertiary hospitals and clinical specimens

Phylogenetic group (PG)	Phylogenetic subgroup (PSG)	Tertiary hospital					PSGP (%)	PGP (%)	Clinical Specimen					
		MNRH	MRRH	MBRRH	KIU-TH	Total			Urine	Blood	Anal swabs	Wound/ pus swabs	Sputum	Trac aspi
A	A0	33 (16.1%)	0 (0.0%)	3 (4.8%)	18 (17.7%)	54	12.8	30.2	19 (15%)	3 (2.4%)	12 (9.5%)	9 (7.1%)	2 (1.6%)	6 (4)
	A1	21 (10.2%)	18 (34.6%)	11 (17.7%)	23 (22.6%)	73	17.3		17 (13.4%)	8 (6.3%)	11 (8.7%)	20 (15.8%)	12 (9.5%)	0 (0)
B1	N/A	38 (18.5%)	14 (26.9%)	17 (27.4%)	22 (21.6%)	91	21.6	21.6	7 (7.7%)	1 (1.1)	74 (81.3%)	3 (3.3%)	3 (3.3%)	1 (1)
B2	B22	6 (1.0%)	2 (3.9%)	4 (6.5%)	3 (2.9%)	15	3.7	41.1	11 (6.4%)	0 (0.0%)	1 (0.6%)	3 (1.7%)	0 (0.0%)	0 (0)
	B23	92 (44.9%)	18 (34.6%)	21 (33.9%)	27 (26.5%)	158	37.5		94 (54.3%)	13 (7.5%)	3 (1.7%)	24 (13.9%)	2 (1.2%)	5 (2)
D	D1	5 (2.4%)	0 (0.0%)	0 (0.0%)	3 (2.9%)	8	1.9	7.1	6 (20.0%)	0 (0.0%)	2 (6.7%)	0 (0.0%)	0 (0.0%)	0 (0)
	D2	10 (4.9%)	0 (0.0%)	6 (9.7%)	6 (5.9%)	22	5.2		16 (53.3%)	3 (10%)	0 (0.0%)	3 (10%)	0 (0.0%)	0 (0)
Total		205	52	62	102	421	100	100	170	28	103	62	19	1

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplTables.docx](#)